52 related articles for article (PubMed ID: 1554799)
21. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group.
Gandara DR; Wold HG; Redmond J; Kohler M; Reynolds R; Wong P; Forsythe J; Fisher K; Lewis B
Semin Oncol; 1986 Mar; 13(1 Suppl 1):14-8. PubMed ID: 3952517
[TBL] [Abstract][Full Text] [Related]
22. Mitoxantrone in the treatment of patients with non-Hodgkin's Lymphoma.
Foss-Abrahamsen A; Lenner P; Hedenus M; Landys K; Noppa H
Cancer Treat Rep; 1987 Dec; 71(12):1209-12. PubMed ID: 3690531
[TBL] [Abstract][Full Text] [Related]
23. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors.
Steward WP; Crowther D; McWilliam LJ; Jones JM; Deakin DP; Todd ID; Blackledge G; Wagstaff J; Scarffe JH; Harris M
Cancer; 1988 Feb; 61(3):441-7. PubMed ID: 3338014
[TBL] [Abstract][Full Text] [Related]
24. [Phase III study of chemotherapy in low-malignancy non-Hodgkin's lymphomas: comparison of vincristine-vindesine combination chemotherapy].
Heim ME; Fritze D; Ho AD; Mebes W; Abel U
Onkologie; 1987 Dec; 10(6):345-8. PubMed ID: 3327022
[TBL] [Abstract][Full Text] [Related]
25. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma.
Al-Ismail SA; Whittaker JA; Gough J
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1379-84. PubMed ID: 3315698
[TBL] [Abstract][Full Text] [Related]
26. Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.
Landys KE
Invest New Drugs; 1988 Jun; 6(2):105-13. PubMed ID: 3170130
[TBL] [Abstract][Full Text] [Related]
27. Value of prednimustine in treating non Hodgkin's lymphomas of favourable histological type.
Klener P; Háber J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):103-8. PubMed ID: 2581855
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Keating MJ; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich EJ; McCredie KB
Blood; 1989 Jul; 74(1):19-25. PubMed ID: 2473795
[TBL] [Abstract][Full Text] [Related]
29. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J
Semin Oncol; 1990 Dec; 17(6 Suppl 10):20-3. PubMed ID: 2259919
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Whelan JS; Davis CL; Rule S; Ranson M; Smith OP; Mehta AB; Catovsky D; Rohatiner AZ; Lister TA
Br J Cancer; 1991 Jul; 64(1):120-3. PubMed ID: 1713049
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine therapy in macroglobulinemic lymphoma.
Kantarjian HM; Alexanian R; Koller CA; Kurzrock R; Keating MJ
Blood; 1990 May; 75(10):1928-31. PubMed ID: 1692487
[TBL] [Abstract][Full Text] [Related]
32. Study of Leo-1031 (NSC-134087) in lymphocytic lymphoma and chronic lymphocytic leukemia.
Kaufman JH; Hanjura GL; Mittelman A; Aungst CW; Murphy GP
Cancer Treat Rep; 1976 Mar; 60(3):277-9. PubMed ID: 946596
[No Abstract] [Full Text] [Related]
33. A clinical staging system for chronic lymphocytic leukemia: prognostic significance.
Binet JL; Leporrier M; Dighiero G; Charron D; D'Athis P; Vaugier G; Beral HM; Natali JC; Raphael M; Nizet B; Follezou JY
Cancer; 1977 Aug; 40(2):855-64. PubMed ID: 890666
[No Abstract] [Full Text] [Related]
34. Continuous treatment of non-Hodgkin's malignant lymphoma with prednimustine (Leo 1031).
Håkansson L; Könyves I; Lindberg LG; Möller T
Oncology; 1978; 35(3):103-6. PubMed ID: 673314
[TBL] [Abstract][Full Text] [Related]
35. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
[TBL] [Abstract][Full Text] [Related]
36. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
Armitage JO; Tobinai K; Hoelzer D; Rummel MJ
Int J Hematol; 2004 May; 79(4):311-21. PubMed ID: 15218957
[TBL] [Abstract][Full Text] [Related]
37. [Non-Hodgkin's lymphoma. Cytology and cytochemistry].
Schwarze EW
Veroff Pathol; 1986; 123():1-241. PubMed ID: 3518274
[TBL] [Abstract][Full Text] [Related]
38. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group.
Brittinger G; Bartels H; Common H; Dühmke E; Fülle HH; Gunzer U; Gyenes T; Heinz R; König E; Meusers P
Hematol Oncol; 1984; 2(3):269-306. PubMed ID: 6384008
[TBL] [Abstract][Full Text] [Related]
39. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
40. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
